SYNTHESIS & IN-VITRO PROTEIN DENATURATION SCREENING OF 2-[(1, 5-DISUBSTITUTEDPHENYL-4,5-DIHYDRO-1H-PYRAZOL-3-YL)OXY]BENZOIC ACID DERIVATIVES
Authors/Creators
- 1. Institute of Pharmacy & Technology, Salipur, Cuttack, Biju Patnaik University of Technology, Odisha, India.
- 2. Netaji Subhas Chandra Bose Institute of Pharmacy, Chakdaha, Nadia, West Bengal, India.
- 3. School of Pharmacy & Life sciences, Centurion University of Technology & Management, Bhubaneswar, Odisha, India.
Description
Abstract
Novel 2-[(1,5-diphenyl-4,5-dihydro-1H-pyrazol-3-yl)oxy]benzoic acid (2a) & 2-[5-(2-hydroxyphenyl)-1-Phenyl-4,5-dihydro-1H-pyrazol-3-yl]benzoic acid (2b) were produced and examined for their in-vitro protein denaturation activities. It was discovered that compound 2b showed promise and had more potency than acetylsalicylic acid (NSAID) in inhibiting denaturation of bovine serum albumin. Docking research also supports this. The compound 2b has the highest docking scores with COX1(PDB ID 3N8Z), COX2 (PDB ID 4PH9), and TNF (PDB ID 2AZ5), respectively, of Etotal -233.75, -256.48, and -255.83. TLC and elemental tests were used to determine the compounds' purity. All of the generated molecules' analytical and spectral data (1H NMR, FTIR, and MS) were entirely consistent with the proposed structures.